Next Issue
Volume 5, June
Previous Issue
Volume 4, December
 
 

Future Pharmacol., Volume 5, Issue 1 (March 2025) – 13 articles

Cover Story (view full-size image):  
  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Select all
Export citation of selected articles as:
14 pages, 8448 KiB  
Article
Interaction of Microcolin Cyanobacterial Lipopeptides with Phosphatidylinositol Transfer Protein (PITP)—Molecular Docking Analysis
by Christian Bailly and Gérard Vergoten
Future Pharmacol. 2025, 5(1), 13; https://doi.org/10.3390/futurepharmacol5010013 - 17 Mar 2025
Viewed by 227
Abstract
Background/Objectives: Microcolins A–M are cytotoxic marine lipopeptides produced by the cyanobacterium Moorena producens, also known as Lyngbya majuscula. Recent studies have shown that two compounds in the series, microcolins B and H, can form covalent complexes with phosphatidylinositol transfer proteins α and [...] Read more.
Background/Objectives: Microcolins A–M are cytotoxic marine lipopeptides produced by the cyanobacterium Moorena producens, also known as Lyngbya majuscula. Recent studies have shown that two compounds in the series, microcolins B and H, can form covalent complexes with phosphatidylinositol transfer proteins α and β (PITPα/β) upon the reaction of their α,β-unsaturated ketone group with the thiol group of a key cysteine residue of PITP. These observations prompted us to compare the binding of all microcolins and a few related derivatives (VT01454 and (deoxy)majusculamide D) to PITP to delineate structure–binding relationships. Methods: A molecular docking analysis led to the identification of microcolin E as the potentially best PITPα binder in the series, followed by microcolins B and H and analog VT01454. The computational data agree well with the published experimental results. Results: The binding of microcolin H into a large cavity of PITPα positions its reactive electrophilic α,β-unsaturated ketone close to the thiol of Cys95, enabling the facile formation of a covalent C-S linkage. A similar bonding can occur with the Cys94 of PITPβ. Molecular models of microcolins bound to PITP were compared to identify structural elements chiefly implicated in the recognition process. Conclusions: This computational study provides guidance in the design of microcolin derivatives targeting PITPα/β considered targets for cancer and inflammatory pathologies. Full article
Show Figures

Graphical abstract

21 pages, 3931 KiB  
Article
Effects of Sinensetin, Eupatilin, and Jaceosidin on Human Melanogenesis: A Pilot Study
by Shilpi Goenka
Future Pharmacol. 2025, 5(1), 12; https://doi.org/10.3390/futurepharmacol5010012 - 14 Mar 2025
Viewed by 427
Abstract
Background/Objectives: Flavones, a class of plant-based flavonoids, have demonstrated conflicting anti-melanogenic activities in mouse and human melanocytes. Sinensetin (SNT), a polymethoxyflavone, has shown pro-melanogenic activity in B16F10 mouse melanoma (MM) cells, while eupatilin (EU) and jaceosidin (JAC), two flavones that are structural analogs [...] Read more.
Background/Objectives: Flavones, a class of plant-based flavonoids, have demonstrated conflicting anti-melanogenic activities in mouse and human melanocytes. Sinensetin (SNT), a polymethoxyflavone, has shown pro-melanogenic activity in B16F10 mouse melanoma (MM) cells, while eupatilin (EU) and jaceosidin (JAC), two flavones that are structural analogs of SNT, have not been evaluated for their effects on melanogenesis yet. Methods: Herein, the effects of SNT, EU, and JAC on melanogenesis in MNT-1 cells (human melanoma) and HEMn-DP cells (primary human melanocytes) have been examined. The mushroom tyrosinase (TYR) activity was tested in cell-free conditions, followed by examination of the cytotoxicity of the compounds via the Alamar Blue (AB) assay. Cellular melanin production and TYR activity were estimated in MNT-1 cells. The compounds were further examined in primary human melanocytes for melanin production, TYR activity, and protein levels. Results: Our findings show that SNT was a potent inhibitor of TYR activity in a cell-free assay, while EU and JAC had no effect. However, both SNT and EU were shown to exhibit anti-melanogenic activity (that was reversible) in human cells, while JAC was ineffective and cytotoxic. Conclusions: SNT and EU are potential novel candidates for hyperpigmentation treatment without cytotoxicity. Additional studies are warranted to elucidate the signaling mechanisms that govern their anti-melanogenesis action. Future research is necessary to assess the anti-melanogenic effectiveness of SNT/EU using 3D skin tissue equivalents and to select the optimal candidate. Full article
Show Figures

Graphical abstract

22 pages, 3077 KiB  
Review
Inter-Tissue Communication Mechanisms via Exosomes and Their Implications in Metabolic Diseases: Opportunities for Pharmacological Regulation
by Brenda Chimal-Vega, Jesus Emanuel Maldonado-Arvizu, Alex Daniel Hernández Avalos, José Fernando Díaz-Villanueva, Luis Pablo Avila-Barrientos and Victor G. García González
Future Pharmacol. 2025, 5(1), 11; https://doi.org/10.3390/futurepharmacol5010011 - 6 Mar 2025
Viewed by 722
Abstract
Exosomes can transport regulatory biomolecules and are mediators of cellular signaling among metabolic tissues through endocrine mechanisms. Understanding the pathways and processes underlying exosome-mediated inter-tissue communication is critical for elucidating the molecular pathophysiology of metabolic diseases such as obesity, type 2 diabetes mellitus [...] Read more.
Exosomes can transport regulatory biomolecules and are mediators of cellular signaling among metabolic tissues through endocrine mechanisms. Understanding the pathways and processes underlying exosome-mediated inter-tissue communication is critical for elucidating the molecular pathophysiology of metabolic diseases such as obesity, type 2 diabetes mellitus (T2DM), and cardiovascular disorders. Consequently, these mechanisms represent novel and promising targets for pharmacological regulation. We examined the current knowledge regarding exosome physiology, the mechanisms of interaction with target tissues, and its role in metabolic tissue communication. We also analyzed the secretory profiles of exosomes in metabolic tissues, emphasizing their regulatory roles in adipose tissue, liver, pancreas, skeletal muscle, and the small intestine, while discussing their association with metabolic diseases. In this sense, we propose the exosomal pentad as a novel framework highlighting exosome-mediated inter-organ communication, where exosomes may regulate a metabolic axis involving these tissues. This model aligns with the ominous octet in type 2 diabetes but emphasizes exosomes as key regulators of metabolic homeostasis and potential therapeutic targets. The role of exosomes for the treatment of metabolic diseases emerges as a critical area of pharmacologic exploration. For instance, therapeutic strategies that prevent target tissue binding or expression of cargo molecules such as miRNAs could be designed, using antagomiRs or nanoparticles. Additionally, integrins like αvβ5 on the exosomal membrane can be blocked with monoclonal antibodies or engineered for targeted delivery of therapeutic molecules. Exosomes, critical mediators of inter-organ communication and metabolic regulation, hold potential to design precise molecular-level therapies while minimizing systemic side effects. Full article
Show Figures

Graphical abstract

12 pages, 3223 KiB  
Article
Water-Soluble Cu(II) Complexes with Polypyridyl Ligands: Anticancer Activity and DNA Interaction
by Herisson F. dos Santos, Nádija N. P. da Silva, George B. S. Pereira, Mauro A. Lima, Nailton M. Nascimento-Júnior, Renan L. de Farias, Amos O. Akinyemi and Fillipe V. Rocha
Future Pharmacol. 2025, 5(1), 10; https://doi.org/10.3390/futurepharmacol5010010 - 19 Feb 2025
Viewed by 612
Abstract
Background/Objectives: Cu(II) complexes with polypyridine ligands have shown carcinogenic activity already described in the literature and appear as a possible alternative to cisplatin, which has several side effects. In view of this, four Cu(II) complexes with the formulas [Cu(L1)(H2O)2](PF [...] Read more.
Background/Objectives: Cu(II) complexes with polypyridine ligands have shown carcinogenic activity already described in the literature and appear as a possible alternative to cisplatin, which has several side effects. In view of this, four Cu(II) complexes with the formulas [Cu(L1)(H2O)2](PF6)2 (A1) and [Cu(L2)(H2O)2](PF6)2 (A2), [Cu(L1)(bipy)](PF6)2 (B1) and [Cu(L2)(bipy)](PF6)2 (B2) were synthesized, where L1 = dipyrido[1,2,5]oxadiazolo[3,4-b]quinoxaline, L2 = 6,7-dicyanodipyrido[2,2-d:2,3-f]quinoxaline, and bipy = 2,2′-bipyridine. Methods: The proposed structures supported characterization techniques (molar conductivity, elemental analyses, absorption spectroscopy in the infrared region, and UV–vis). The interaction of the complexes with DNA was evaluated through an ethidium bromide displacement assay, complemented by theoretical studies using molecular docking. Additionally, the cytotoxic activity of the complexes was tested against DU 145 (prostate tumor), MCF-7 (breast tumor), and PNT-2 (non-tumor prostate) cell lines, with all complexes showing promising results. Results: Among them, complex B1 exhibited the highest number of DNA contacts in molecular docking studies, a binding constant of 3.7 × 106 in the ethidium bromide displacement assay. It was the most selective complex (IS = 5.43) for the DU 145 (prostate tumor) cell line, demonstrating greater selectivity than cisplatin. Conclusions: This study has demonstrated the potential of the Cu(II) complexes obtained, which could be an alternative to platinum complexes in the future Full article
(This article belongs to the Special Issue Feature Papers in Future Pharmacology 2024)
Show Figures

Graphical abstract

22 pages, 3780 KiB  
Article
Discovery of Arylfuran and Carbohydrate Derivatives from the BraCoLi Library as Potential Zika Virus NS3pro Inhibitors
by Fernanda Kelly Marcelino e Oliveira, Beatriz Murta Rezende Moraes Ribeiro, Ellen Gonçalves de Oliveira, Marina Mol Sena Andrade Verzola, Thales Kronenberger, Vinícius Gonçalves Maltarollo, Ricardo José Alves, Renata Barbosa de Oliveira, Rafaela Salgado Ferreira, Jônatas Santos Abrahão and Mateus Sá Magalhães Serafim
Future Pharmacol. 2025, 5(1), 9; https://doi.org/10.3390/futurepharmacol5010009 - 15 Feb 2025
Viewed by 447
Abstract
Background/Objectives: Zika fever is a disease caused by the Zika virus (ZIKV). Symptomatic cases may be associated with neurological disorders in adults, as well as congenital Zika syndrome and other birth defects during pregnancy. In 2016, Zika fever was considered a public health [...] Read more.
Background/Objectives: Zika fever is a disease caused by the Zika virus (ZIKV). Symptomatic cases may be associated with neurological disorders in adults, as well as congenital Zika syndrome and other birth defects during pregnancy. In 2016, Zika fever was considered a public health problem by the World Health Organization (WHO), highlighting the need to develop new therapies against the disease. Currently, there is no antiviral or vaccine available to treat or prevent severe cases. Due to the lack of available therapeutics and few promising hit molecules, we computationally screened the well-described ZIKV protease (NS3pro) as a drug target to revisit the small-molecule database Brazilian Compound Library (BraCoLi) and select potential inhibitors. Methods: We employed a consensus docking screening of a library of 1176 compounds using GOLD and DockThor. We selected 28 hits based on predicted binding affinity, and only the remnants of three compounds were available in the library at the time of this study for experimental validation. The hits were evaluated for their cytotoxic (CC50) and effective concentrations (EC50) for their potential antiviral activity in Vero cells. Results: The three hit compounds presented modest CC50 values of 89.15 ± 3.72, >100, and 29.67 ± 1.01 μM, with the latter, a carbohydrate derivative, having an EC50 value of >12.5 μM (~40% inhibition) against ZIKV PE243. Additionally, the essentially non-toxic compound, an arylfuran derivative, also inhibited the ZIKV NS3pro with an IC50 value of 17 μM but presented evidence of acting through a promiscuous mechanism for enzyme inhibition. Conclusion: This study highlights the relevance of revisiting existing small-molecule assets to identify novel therapeutic starting points against ZIKV, aiming for potential lead candidates in the future. Full article
Show Figures

Graphical abstract

17 pages, 4156 KiB  
Communication
The Effect of Agave Bagasse Extract on Wound Healing in a Murine Model
by Herminia López-Salazar, Elizabeth Negrete-León, Brenda Hildeliza Camacho-Díaz, Juan José Acevedo-Fernández, Sandra Victoria Ávila-Reyes and Martha L. Arenas Ocampo
Future Pharmacol. 2025, 5(1), 8; https://doi.org/10.3390/futurepharmacol5010008 - 5 Feb 2025
Cited by 1 | Viewed by 551
Abstract
Background/Objectives: The development of bioproducts that can accelerate wound healing is a key focus in biomedicine, especially when these products are derived from sustainable by-products. This study investigates the wound-healing potential of an extract obtained from Agave angustifolia Haw bagasse (BagEE) using microwave [...] Read more.
Background/Objectives: The development of bioproducts that can accelerate wound healing is a key focus in biomedicine, especially when these products are derived from sustainable by-products. This study investigates the wound-healing potential of an extract obtained from Agave angustifolia Haw bagasse (BagEE) using microwave extraction.Methods: HPLC-MS analysis was performed to identify the main compounds present in BagEE, revealing quercetin, isorhamnetin, diosgenin, hecogenin, manogenin, β-sitosterol glucoside, and β-sitosterol as tentative constituents. A murine excision wound model was employed to assess the efficacy of BagEE. The experimental group received a topical application of 8 mg of BagEE, while the control group was treated with water only. Wound closure, re-epithelialization, and collagen deposition were evaluated to determine the effects of BagEE on skin healing. Results: The BagEE-treated group exhibited significantly accelerated wound healing, achieving a 99.4% closure rate by day 13 compared to the control group’s 92.8% closure rate on day 22. Additionally, wounds treated with BagEE displayed complete re-epithelialization and a well-organized skin structure. Conclusions: These findings suggest that BagEE promotes effective wound healing and shows promise as a topical agent for skin regeneration. Further studies are necessary to investigate its anti-inflammatory and wound-healing activities in both in vivo and in vitro settings. Full article
Show Figures

Graphical abstract

16 pages, 1006 KiB  
Review
Why Do Glioblastoma Treatments Fail?
by Alen Rončević, Nenad Koruga, Anamarija Soldo Koruga and Robert Rončević
Future Pharmacol. 2025, 5(1), 7; https://doi.org/10.3390/futurepharmacol5010007 - 1 Feb 2025
Viewed by 759
Abstract
Glioblastoma (GBM) is the most aggressive brain tumor, characterized by high recurrence rates and poor patient outcomes. Treatment failure is driven by multiple factors, including complex tumor heterogeneity, the presence of cancer stem cells, the immunosuppressive tumor microenvironment (TME), and many others. GBM’s [...] Read more.
Glioblastoma (GBM) is the most aggressive brain tumor, characterized by high recurrence rates and poor patient outcomes. Treatment failure is driven by multiple factors, including complex tumor heterogeneity, the presence of cancer stem cells, the immunosuppressive tumor microenvironment (TME), and many others. GBM’s heterogeneity underlines its ability to resist therapies and adapt to the TME. The TME, which is highly immunosuppressive and shaped by hypoxia, impairs anti-tumor immunity and limits the efficacy of immunotherapy. The blood–brain barrier (BBB) remains a major obstacle to delivering sufficient drug concentrations to the tumor by restricting the penetration of therapeutic agents. Another problem is the lack of reliable biomarkers to perform better patient stratification or even guide personalized treatments, resulting in generalized therapeutic approaches that do not adequately address GBM complexities. This review highlights the multifactorial nature of GBM treatment failure and highlights the need for a paradigm shift and innovative, personalized strategies. A deeper understanding of tumor biology and advances in translational research will be crucial to developing effective therapies and improving patient outcomes in this devastating disease. Full article
(This article belongs to the Special Issue Feature Papers in Future Pharmacology 2024)
Show Figures

Figure 1

11 pages, 1358 KiB  
Communication
Anti-Inflammatory Potential of Umckalin Through the Inhibition of iNOS, COX-2, Pro-Inflammatory Cytokines, and MAPK Signaling in LPS-Stimulated RAW 264.7 Cells
by So-Yeon Oh and Chang-Gu Hyun
Future Pharmacol. 2025, 5(1), 6; https://doi.org/10.3390/futurepharmacol5010006 - 21 Jan 2025
Viewed by 1005
Abstract
Background/Objectives: Umckalin, a coumarin derivative abundantly present in the root extract of Pelargonium sidoides, is a key bioactive compound known for its antimicrobial, antiviral, antitubercular, and immunomodulatory properties. Its therapeutic potential has been extensively studied, particularly in the context of respiratory diseases. [...] Read more.
Background/Objectives: Umckalin, a coumarin derivative abundantly present in the root extract of Pelargonium sidoides, is a key bioactive compound known for its antimicrobial, antiviral, antitubercular, and immunomodulatory properties. Its therapeutic potential has been extensively studied, particularly in the context of respiratory diseases. This study aimed to evaluate the potential of umckalin as a therapeutic agent for chronic inflammatory diseases and to elucidate its underlying mechanisms of action. Methods: Using lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages as an experimental model, we investigated the inhibitory effects of umckalin on inflammatory mediators and cytokine production. We measured levels of nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β), and assessed the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Additionally, the regulation of MAPK signaling pathways, including JNK, p38 MAPK, and ERK, was analyzed. Results: The results demonstrated that umckalin significantly reduced the levels of NO, PGE2, TNF-α, IL-6, and IL-1β in LPS-stimulated RAW 264.7 cells. Umckalin also suppressed the expression of iNOS and COX-2, leading to decreased NO and PGE2 production. Furthermore, umckalin effectively regulated inflammatory responses by reducing the phosphorylation of MAPK signaling pathways, including JNK, p38 MAPK, and ERK. Conclusions: These findings indicate that umckalin inhibits the production of TNF-α, IL-6, IL-1β, and NO, while regulating MAPK signaling pathways, thereby suppressing the expression of iNOS and COX-2. This study highlights the potent anti-inflammatory effects of umckalin and suggests its potential as a promising candidate for the treatment of chronic inflammatory diseases. Full article
(This article belongs to the Special Issue Novel Therapeutic Approach to Inflammation and Pain)
Show Figures

Figure 1

17 pages, 974 KiB  
Review
An Overview of Sargassum Seaweed as Natural Anticancer Therapy
by Kelly Johanna Muñoz-Losada, Manuela Gallego-Villada and Miguel Angel Puertas-Mejía
Future Pharmacol. 2025, 5(1), 5; https://doi.org/10.3390/futurepharmacol5010005 - 20 Jan 2025
Viewed by 1229
Abstract
Algae have great therapeutic value and have attracted a great deal of attention due to the abundance of bioactive compounds they contain, which may be the key to fighting diseases of various origins, such as skin cancer, breast cancer, or osteosarcoma. In this [...] Read more.
Algae have great therapeutic value and have attracted a great deal of attention due to the abundance of bioactive compounds they contain, which may be the key to fighting diseases of various origins, such as skin cancer, breast cancer, or osteosarcoma. In this regard, global trends indicate that cancer is likely to become the leading cause of death and the main obstacle to increased life expectancy in the 21st century, which is related to multiple factors, including the various effects of climate change, which will continue to cause afflictions to human health. Then, excess exposure to ultraviolet radiation (UVR) causes damage to DNA, proteins, enzymes, and various cellular structures and leads to the development of cancer, premature aging of the skin (wrinkles, dryness, dilation of blood vessels, and loss of collagen and elastin), or alterations of the immune system. In addition, multidrug resistance (MDR) is characterized by the overexpression of efflux pumps, such as P-glycoprotein or P-gp, that expel chemotherapeutic drugs out of the cancer cell being the main obstacle to their efficacy. Some molecules inhibit efflux pumps when co-administered with antineoplastic agents, such as glycolipids. Mycosporin-like amino acids and glycolipids isolated from Sargassum have shown an important role as potential anticancer agents. The results show that glycolipids and mycosporin-like amino acids present in brown algae of the genus Sargassum exhibit cytotoxic effects on different types of cancer, such as breast cancer, leukemia, and osteosarcoma, which is a key criterion to be considered as a natural anti-cancer strategy; but, more in-depth in vitro studies are needed to represent them at the in vivo level, as well as their validation in preclinical assays. Full article
(This article belongs to the Special Issue Feature Papers in Future Pharmacology 2024)
Show Figures

Graphical abstract

19 pages, 924 KiB  
Review
Prospect of (Nd3+) Complexes and Its Nanoparticles as Promising Novel Anticancer Agents in Particular Targeting Breast Cancer Cell Lines
by Faraj Ahmad Abuilaiwi
Future Pharmacol. 2025, 5(1), 4; https://doi.org/10.3390/futurepharmacol5010004 - 14 Jan 2025
Viewed by 753
Abstract
Breast cancer is the leading cause of tumor-related death in women around much of the world and a major health burden for modern medicine. This review highlights the prospect of (Nd3+) complexes and nanoparticles as promising novel anticancer agents in particular [...] Read more.
Breast cancer is the leading cause of tumor-related death in women around much of the world and a major health burden for modern medicine. This review highlights the prospect of (Nd3+) complexes and nanoparticles as promising novel anticancer agents in particular targeting breast cancer cell lines. This study emphasizes the therapeutic and diagnostic potentials of Nd3+-based metal complexes, especially in reversing drug resistance or enhancing targeted therapy. A comprehensive overview of diagnostic modalities underscores the imperative for the prompt identification and intervention of breast cancer. Nd3+ complexes demonstrate potential as anticancer therapeutics due to their significant cytotoxicity evidenced by their IC50 values. The research outcomes indicated that it could theoretically inhibit the growth and metastasis of cancer cell lines. Future research should focus on synthesizing novel Nd3+ complexes with enhanced bioavailability, solubility, and reduced toxicity to further advance their application. Full article
(This article belongs to the Special Issue Feature Papers in Future Pharmacology 2024)
Show Figures

Scheme 1

20 pages, 1653 KiB  
Review
An Updated Review of the Antimicrobial Potential of Selenium Nanoparticles and Selenium-Related Toxicological Issues
by Tainá Pereira da Silva Oliveira, Alan Kelbis Oliveira Lima and Luís Alexandre Muehlmann
Future Pharmacol. 2025, 5(1), 3; https://doi.org/10.3390/futurepharmacol5010003 - 8 Jan 2025
Cited by 1 | Viewed by 916
Abstract
Discovered in mid-1817 by Jöns Jacob Berzelius, selenium, belonging to Group 16 of the periodic table is an essential trace element for human and animal health, due to its biocompatibility and bioavailability. Additionally, it is known for having different oxidation states, which allows [...] Read more.
Discovered in mid-1817 by Jöns Jacob Berzelius, selenium, belonging to Group 16 of the periodic table is an essential trace element for human and animal health, due to its biocompatibility and bioavailability. Additionally, it is known for having different oxidation states, which allows it to interact with distinct chemical elements to form various compounds. Selenium exhibits two forms, organic and inorganic; the latter is known for its genotoxicity. Selenium nanoparticles have been investigated as an alternative to mitigate the toxicity of this element. With antidiabetic, antiviral, chemopreventive, and antimicrobial properties, SeNPs possess significant biomedical potential and can be synthesized using chemical, physical, or green methods, offering new solutions for combating microbial resistance and other diseases. This review discusses the historical discovery of selenium, preparation methods, the versatility of combinations for synthesis, morphological characteristics, and sizes, as well as the impact of SeNP applications obtained through different approaches against medically relevant microorganisms, particularly those exhibiting resistance to conventional antimicrobials. Full article
Show Figures

Figure 1

2 pages, 123 KiB  
Editorial
2025: A Bright Year Ahead for Future Pharmacology
by Fabrizio Schifano
Future Pharmacol. 2025, 5(1), 2; https://doi.org/10.3390/futurepharmacol5010002 - 1 Jan 2025
Viewed by 900
Abstract
As 2024 is coming to an end, let us reflect on Future Pharmacology’s achievements to better understand what is promising to be a bright year ahead [...] Full article
14 pages, 988 KiB  
Review
Sodium Nitroprusside: The Forgotten Vasodilator? A Brief Guide for Informed and Safe Use from Heart Failure to Hypertensive Crisis and Aortic Dissection
by Saverio D’Elia, Rosa Franzese, Carmine Gentile, Achille Solimene, Ettore Luisi, Antonio Caiazzo, Francesco Natale, Francesco S. Loffredo, Paolo Golino and Giovanni Cimmino
Future Pharmacol. 2025, 5(1), 1; https://doi.org/10.3390/futurepharmacol5010001 - 26 Dec 2024
Cited by 1 | Viewed by 4567
Abstract
Sodium nitroprusside (SNP) is a powerful vasodilator approved for treating acute hypertensive crises, acute heart failure, aortic dissection, and both controlled perioperative hypotension and perioperative hypertension. Its unique ability to cause both venous and arterial dilation makes it an invaluable option in critical [...] Read more.
Sodium nitroprusside (SNP) is a powerful vasodilator approved for treating acute hypertensive crises, acute heart failure, aortic dissection, and both controlled perioperative hypotension and perioperative hypertension. Its unique ability to cause both venous and arterial dilation makes it an invaluable option in critical care settings. Despite concerns regarding its manageability due to potential toxicity, it is a safe choice if properly used, as highlighted by its short half-life and minimal side effects. This review aims to summarize its pharmacological properties, toxicology, and various clinical applications, particularly focusing on acute heart failure and hypertensive emergencies. Full article
(This article belongs to the Special Issue Feature Papers in Future Pharmacology 2024)
Show Figures

Graphical abstract

Previous Issue
Next Issue
Back to TopTop